Alternatives for Reducing Chorea in Huntington Disease
Completed
Auspex Pharmaceuticals, Inc.
Phase 3
2013-11-12
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In
addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed
in "Switch" participants as well as "Rollover" participants completing a randomized, double
blind, placebo-controlled study of SD-809 ER.
The purpose of this study is to determine whether an investigational drug, SD-809
(deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive
dyskinesia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
